Atrial natriuretic peptide increases inflammation, infarct size, and mortality after experimental coronary occlusion

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 296, Issue 3, 2009, Pages

  Houng, Aiilyan K ^a,b   McNamee, Rachel A ^a   Kerner, Attila ^a   Sharma, Pallavi ^a   Mohamad, Almois ^a   Tronolone, Jonathan ^a   Reed, Guy L ^a,b,c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c D334 Coleman ^*  (United States)

Author keywords

Myocardial infarction; Neutrophil; P selectin

Indexed keywords

ATRIAL NATRIURETIC FACTOR; PADGEM PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL INFILTRATION; CELL MIGRATION; CONGENIC STRAIN; CONTROLLED STUDY; CORONARY ARTERY; DISEASE COURSE; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; INFLAMMATION; MALE; MORTALITY; MOUSE; NEUTROPHIL; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SHAM PROCEDURE; SURVIVAL; VASCULARIZATION; WILD TYPE; ANIMAL; C57BL MOUSE; CARDIOMEGALY; DISEASE MODEL; GENETICS; HEART CONTRACTION; HEMODYNAMICS; INFUSION PUMP; METABOLISM; MOUSE MUTANT; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PATHOPHYSIOLOGY; TIME;

ANIMALS; ATRIAL NATRIURETIC FACTOR; CARDIOMEGALY; CORONARY OCCLUSION; DISEASE MODELS, ANIMAL; HEMODYNAMICS; INFLAMMATION; INFUSION PUMPS, IMPLANTABLE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIUM; NEUTROPHIL INFILTRATION; P-SELECTIN; TIME FACTORS;

EID: 64049094156     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00684.2008     Document Type: Article

References (44)

1. Angelis E, Tse MY, Pang SC. Interactions between atrial natriuretic peptide and the renin-angiotensin system during salt-sensitivity exhibited by the proANP gene-disrupted mouse. Mol Cell Biochem 276: 121-131, 2005.
2. Askari AT, Brennan ML, Zhou X, Drinko J, Morehead A, Thomas JD, Topol EJ, Hazen SL, Penn MS. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med 197: 615-624, 2003.
3. Bayat H, Swaney JS, Ander AN, Dalton N, Kennedy BP, Hammond HK, Roth DM. Progressive heart failure after myocardial infarction in mice. Basic Res Cardiol 97: 206-213, 2002.
4. Biselli R, Farrace S, De Simone C, Fattorossi A. Potentiation of human polymorphonuclear leukocyte activation by atrial natriuretic peptide. Inhibitory effect of carnitine congeners. Inflammation 20: 33-42, 1996.
5. Chen HH, Cataliotti A, Schirger JA, Martin FL, Burnett JC Jr. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure. Am J Physiol Regul Integr Comp Physiol 288: R1093-R1097, 2005.
6. Clements-Jewery H, Hearse DJ, Curtis MJ. Neutrophil ablation with anti-serum does not protect against phase 2 ventricular arrhythmias in anaesthetised rats with myocardial infarction. Cardiovasc Res 73: 761-769, 2007.
7. De Caterina R, Volpe M, Atlas SA, Weksler BB. Effects of atrial natriuretic factor on human platelet function. Life Sci 37: 1395-1402, 1985.
8. De Celle T, Vanrobaeys F, Lijnen P, Blankesteijn WM, Heeneman S, Van Beeumen J, Devreese B, Smits JF, Janssen BJ. Alterations in mouse cardiac proteome after in vivo myocardial infarction: permanent ischaemia versus ischaemia-reperfusion. Exp Physiol 90: 593-606, 2005.
9. De Servi S, Mazzone A, Ricevuti G, Fioravanti A, Bramucci E, Angoli L, Stefano G, Specchia G. Granulocyte activation after coronary angioplasty in humans. Circulation 82: 140-146, 1990.
10. Deschepper CF. The many possible benefits of natriuretic peptides after myocardial infarction. Hypertension 46: 271-272, 2005.
11. Dewald O, Ren G, Duerr GD, Zoerlein M, Klemm C, Gersch C, Tincey S, Michael LH, Entman ML, Frangogiannis NG. Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. Am J Pathol 164: 665-677, 2004.
12. Entman ML, Michael L, Rossen RD, Dreyer WJ, Anderson DC, Taylor AA, Smith CW. Inflammation in the course of early myocardial ischemia. FASEB J 5: 2529-2537, 1991.
13. Harada K, Sugaya T, Murakami K, Yazaki Y, Komuro I. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 100: 2093-2099, 1999.
14. Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutsui T, Horie H, Ohnishi M, Kinoshita M. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 37: 1820-1826, 2001.
15. Hoshida S, Kuzuya T, Nishida M, Kim Y, Kitabatake A, Kamada T, Tada M. Attenuation of neutrophil function by inhibitors of arachidonate metabolism reduces the extent of canine myocardial infarction. Am J Cardiol 63: 24E-28E, 1989.
16. Huggins GS, Lepore JJ, Greytak S, Patten R, McNamee R, Aronovitz M, Wang PJ, Reed GL. The CREB leucine zipper regulates CREB phosphorylation, cardiomyopathy, and lethality in a transgenic model of heart failure. Am J Physiol Heart Circ Physiol 293: H1877-H1882, 2007.
17. Izumi T, Saito Y, Kishimoto I, Harada M, Kuwahara K, Hamanaka I, Takahashi N, Kawakami R, Li Y, Takemura G, Fujiwara H, Garbers DL, Mochizuki S, Nakao K. Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF-kappaB activation and alleviates myocardial ischemia/reperfusion injury. J Clin Invest 108: 203-213, 2001.
18. John SW, Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC, Flynn TG, Smithies O. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 267: 679 -681, 1995.
19. Jordan JE, Zhao ZQ, Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res 43: 860-878, 1999.
20. Kawakami R, Saito Y, Kishimoto I, Harada M, Kuwahara K, Takahashi N, Nakagawa Y, Nakanishi M, Tanimoto K, Usami S, Yasuno S, Kinoshita H, Chusho H, Tamura N, Ogawa Y, Nakao K. Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction. Circulation 110: 3306-3312, 2004.
21. Kin H, Wang NP, Halkos ME, Kerendi F, Guyton RA, Zhao ZQ. Neutrophil depletion reduces myocardial apoptosis and attenuates NFkappaB activation/TNFalpha release after ischemia and reperfusion. J Surg Res 135: 170-178, 2006.
22. Kinugawa S, Tsutsui H, Hayashidani S, Ide T, Suematsu N, Satoh S, Utsumi H, Takeshita A. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ Res 87: 392-398, 2000.
23. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, Seguchi O, Myoishi M, Minamino T, Ohara T, Nagai Y, Nanto S, Watanabe K, Fukuzawa S, Hirayama A, Nakamura N, Kimura K, Fujii K, Ishihara M, Saito Y, Tomoike H, Kitamura S. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 370:1483-1493, 2007.
24. Lang CC, Lau CS, Belch JJ, Struthers AD. Effect of atrial natriuretic factor on platelet function in whole blood ex-vivo in man. Eur J Clin Pharmacol 39: 589-591, 1990.
25. Lefer AM. Role of selectins in myocardial ischemia-reperfusion injury. Ann Thorac Surg 60: 773-777, 1995.
26. Loeb AL, Gear AR. Potentiation of platelet aggregation by atrial natriuretic peptide. Life Sci 43: 731-738, 1988.
27. Lowe JE, Reimer KA, Jennings RB. Experimental infarct size as a function of the amount of myocardium at risk. Am J Pathol 90: 363-379, 1978.
28. Lutgens E, Daemen MJ, de Muinck ED, Debets J, Leenders P, Smits JF. Chronic myocardial infarction in the mouse: cardiac structural and functional changes. Cardiovasc Res 41: 586-593, 1999.
29. McGrath MF, de Bold AJ. Determinants of natriuretic peptide gene expression. Peptides 26: 933-943, 2005.
30. Nakanishi M, Saito Y, Kishimoto I, Harada M, Kuwahara K, Takahashi N, Kawakami R, Nakagawa Y, Tanimoto K, Yasuno S, Usami S, Li Y, Adachi Y, Fukamizu A, Garbers DL, Nakao K. Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice. Hypertension 46:441-447, 2005.
31. Nakayama T. The genetic contribution of the natriuretic peptide system to cardiovascular diseases. Endocr J 52: 11-21, 2005.
32. O'Tierney PF, Komolova M, Tse MY, Adams MA, Pang SC. Altered regulation of renal interstitial hydrostatic pressure and the renal renin- angiotensin system in the absence of atrial natriuretic peptide. J Hypertens 26: 303-311, 2008.
33. Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL, Pandey KN, Milgram SL, Smithies O, Maeda N. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci USA 94: 14730-14735, 1997.
34. Palazzo AJ, Jones SP, Anderson DC, Granger DN, Lefer DJ. Coronary endothelial P-selectin in pathogenesis of myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 275: H1865-H1872, 1998.
35. Patten RD, Aronovitz MJ, Einstein M, Lambert M, Pandian NG, Mendelsohn ME, Konstam MA. Effects of angiotensin II receptor blockade versus angiotensin-converting-enzyme inhibition on ventricular remodelling following myocardial infarction in the mouse. Clin Sci (Lond) 104: 109 -118, 2003.
36. Rastegar MA, Vegh A, Papp JG, Parratt JR. Atrial natriuretic peptide reduces the severe consequences of coronary artery occlusion in anaesthetized dogs. Cardiovasc Drugs Ther 14: 471-479, 2000.
37. Romson JL, Hook BG, Kunkel SL, Abrams GD, Schork MA, Lucchesi BR. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation 67: 1016 -1023, 1983.
38. Rubattu S, Volpe M. The atrial natriuretic peptide: a changing view. J Hypertens 19: 1923-1931, 2001.
39. Saraiva RM, Minhas KM, Raju SV, Barouch LA, Pitz E, Schuleri KH, Vandegaer K, Li D, Hare JM. Deficiency of neuronal nitric oxide synthase increases mortality and cardiac remodeling after myocardial infarction: role of nitroso-redox equilibrium. Circulation 112: 3415-3422, 2005.
40. Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit-Faisant B, Carayon A, Swynghedauw B, Delcayre C. Activation of cardiac aldo-sterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 99: 2694-2701, 1999.
41. Takagi G, Kiuchi K, Endo T, Yamamoto T, Sato N, Nejima J, Takano T. Alpha-human atrial natriuretic peptide, carperitide, reduces infarct size but not arrhythmias after coronary occlusion/reperfusion in dogs. J Cardiovasc Pharmacol 36: 22-30, 2000.
42. Tarnavski O, McMullen JR, Schinke M, Nie Q, Kong S, Izumo S. Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies. Physiol Genomics 16: 349 -360, 2004.
43. Vollmar AM. The role of atrial natriuretic peptide in the immune system. Peptides 26: 1086-1094, 2005.
44. Wiedermann CJ, Wiedermann FJ, Herold M, Tilg H, Moes N, Muhlberger V, Beimpold H, Knapp E. Plasma levels of atrial natriuretic peptide and tumor necrosis factor-alpha during transient myocardial ischemia in patients with stable angina. Klin Wochenschr 69: 944, 1991.